← Insider buys

Fred P. Lampropoulos has sold MMSI and made no open-market buys since Nov 2025

Executive Chair at Merit Medical Systems, Inc.

SEC CIK 0000901534 · Filings on SEC.gov ↗

$0Bought
$3.1MSold
NoneLast buy

Every filing

2 filings since Nov 2025, newest first

About Fred P. Lampropoulos

Fred P. Lampropoulos is a corporate executive and medical device entrepreneur who serves as Executive Chairman and Chairman of the Board of Merit Medical Systems, Inc. (NASDAQ: MMSI), where he has been a key insider and long‑time leader.( He founded Merit Medical in 1987, growing it from a single innovation—a stronger, safer disposable syringe—into a global manufacturer and marketer of proprietary disposable medical devices used in interventional, diagnostic, and therapeutic procedures, particularly in cardiology, radiology, oncology, critical care, and endoscopy.( Under his leadership, Merit has expanded internationally and amassed hundreds of patents and pending applications covering thousands of device inventions used worldwide.(

Lampropoulos has spent nearly three decades in the medical device industry, previously serving as Chairman and CEO of Utah Medical and founding Sentir Semiconductors in 1991, now Merit Sensor Systems, a subsidiary of Merit Medical.( He has also held senior roles beyond Merit, including President of BioSphere Medical, Inc., Chairman of BioUtah, and directorships at companies such as Vysera Biomedical.( Widely recognized for his contributions, he has been inducted into the University of Utah College of Science Hall of Fame, the Utah Business Hall of Fame, and the Utah Technology Hall of Fame, and has received honors such as the Governor’s Medal for Science and Technology, MWCN Entrepreneur of the Year, the Utah National Guard Bronze Minuteman Award, and BioUtah’s Executive of the Year.( In addition to his corporate work, Lampropoulos is active in civic and philanthropic initiatives, supporting arts, sciences, and community organizations including homeless and youth centers.(

Written by Perplexity from public sources.

Filings come from SEC EDGAR. Not investment advice.